Cited in:


This article has been cited by:

  1. 1
    Paul M. Scola, Alan Xiangdong Wang, Andrew C. Good, Li-Qiang Sun, Keith D. Combrink, Jeffrey A. Campbell, Jie Chen, Yong Tu, Ny Sin, Brian L. Venables, Sing-Yuen Sit, Yan Chen, Anthony Cocuzza, Donna M. Bilder, Stanley D’Andrea, Barbara Zheng, Piyasena Hewawasam, Min Ding, Jan Thuring, Jianqing Li, Dennis Hernandez, Fei Yu, Paul Falk, Guangzhi Zhai, Amy K. Sheaffer, Chaoqun Chen, Min S. Lee, Diana Barry, Jay O. Knipe, Wenying Li, Yong-Hae Han, Susan Jenkins, Christoph Gesenberg, Qi Gao, Michael W. Sinz, Kenneth S. Santone, Tatyana Zvyaga, Ramkumar Rajamani, Herbert E. Klei, Richard J. Colonno, Dennis M. Grasela, Eric Hughes, Caly Chien, Stephen Adams, Paul C. Levesque, Danshi Li, Jialong Zhu, Nicholas A. Meanwell, Fiona McPhee, Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection, Journal of Medicinal Chemistry, 2014, 57, 5, 1708


  2. 2
    S. BALTER, J. H. STARK, J. KENNEDY, K. BORNSCHLEGEL, K. KONTY, Estimating the prevalence of hepatitis C infection in New York City using surveillance data, Epidemiology and Infection, 2014, 142, 02, 262


  3. You have free access to this content3
    Marc Bourlière, Xavier Adhoute, Astrid Wendt, Christelle Ansaldi, Valérie Oules, Paul Castellani, How to optimize current therapy of HCV genotype 1 infection with boceprevir, Liver International, 2014, 34,
  4. You have free access to this content4
    B. Maasoumy, K. Port, B. Calle Serrano, A. A. Markova, L. Sollik, M. P. Manns, M. Cornberg, H. Wedemeyer, The clinical significance of drug–drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C, Alimentary Pharmacology & Therapeutics, 2013, 38, 11-12